What is Cardiosense?
Cardiosense operates as a high-growth digital health enterprise specializing in the development of sophisticated biomarker platforms. The company integrates innovative multi-sensor hardware with proprietary AI-driven software to identify early indicators of cardiac disease. By providing medical-grade monitoring solutions that are both device-agnostic and data-rich, Cardiosense enables healthcare providers to transition toward more personalized, proactive treatment models. Their market position is defined by a commitment to enhancing patient outcomes through actionable physiological insights, effectively bridging the gap between raw data collection and clinical decision-making.
How much funding has Cardiosense raised?
Cardiosense has raised a total of $15.1M across 1 funding round:
Series A
$15.1M
Series A (2022): $15.1M with participation from UnityPoint Health Ventures, OSF Ventures, Broadview Ventures, Laerdal Million Lives Fund, Hatteras Venture Partners, and Portal Innovations
Key Investors in Cardiosense
UnityPoint Health Ventures
The venture capital arm of one of the nation's largest integrated health systems, focusing on investments that improve patient outcomes and reduce healthcare costs.
OSF Ventures
A division of OSF HealthCare that specializes in venture optimization, partnering with companies to improve clinical outcomes and operational efficiency.
Broadview Ventures
An impact-focused investment firm dedicated to accelerating the development of innovative technologies specifically for the diagnosis and treatment of cardiovascular disease and stroke.
What's next for Cardiosense?
With this major enterprise-level funding, Cardiosense is poised to expand its footprint in the cardiovascular monitoring market. The strategic roadmap likely includes the scaling of its clinical AI capabilities and the broadening of its commercial partnerships with major health systems. As the company moves beyond its initial development phase, the focus will shift toward widespread clinical adoption and the integration of its diagnostic tools into standard care pathways. Investors are looking for the firm to demonstrate sustained efficacy in reducing healthcare costs while simultaneously improving the quality of life for patients at risk of cardiac events.
See full Cardiosense company page
